Remove topics patented-medicines
article thumbnail

Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal

IIPRD

Here, developing a new medicine requires substantial investment which comes with a high degree of uncertainty. [iv] v] This, in turn, can lead to significant price hikes for essential medicines. The inclusion of TRIPS-plus provisions within trade agreements presents a potential challenge to global access to essential medicines.

article thumbnail

Pharma and medical device regulation – GTDT – Lexology

Olartemoure Blog

We touch on topics like its regulatory framework, clinical practice, marketing authorization, amending authorizations, recall, promotion, enforcement of advertising rules, pricing and reimbursement, off-label use and unlicensed products, sale and supply, and recent trends that have been noticed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Place Where Science Business Meet: My Internship Experience at AstraZeneca Canada

IPilogue

I was pleased to gain exposure to a variety of topics including patent litigation, pharmaceutical regulations, and privacy law over the course of my internship. As a multinational pharmaceutical company, AstraZeneca is often involved in complex patent litigation.

Business 106
article thumbnail

[Sponsored] Short Course on ‘Pharmaceuticals and IP’ by British Institute of International and Comparative Law [March 4 – May 13]

SpicyIP

Although the business and innovation practices of the pharmaceutical industry are largely based on patents, other intellectual property rights including trade marks and trade secrets are highly relevant too. Course Topics. Personalised and precision medicine; digital medicine. What does the pharmaceutical industry patent?

article thumbnail

How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently

The IPKat

However the two recent posts of this very same blog, one on the preliminary opinion of EBA on plausibility (G2/21, here ), the other on the requisite of sufficiency of disclosure for a first medical use patent (T0424/21, here ) have removed any doubt on whether or not to try and cover it.

IP 76
article thumbnail

European Commission consultation on unitary supplementary protection certificates (SPCs)

The IPKat

The purpose of the SPC Regulations ( Regulation (EC) No 469/2009 and Regulation (EC) No 1610/96 ) is to compensate patentees for the lengthy process of achieving marketing authorisation for a medicinal or plant product. SPCs are national rights that provide an additional period of protection for a medicinal product protected by a patent.

article thumbnail

[Guest post] Conference Report: Fourth IP & Innovation Researchers of Asia Conference

The IPKat

Spread over 4 days to accommodate many exciting topics and parallel sessions, over 160 presenters from all over the world logged in to experience upcoming Intellectual Property law scholarship. These sessions were chaired by renowned and distinguished IP scholars and officials from WIPO and WTO.